Morphiex Biotherapeutics | morphiex
1
archive,author,author-morphiex,author-1,ajax_fade,page_not_loaded,,qode-content-sidebar-responsive,qode-theme-ver-13.8,qode-theme-bridge,disabled_footer_top,disabled_footer_bottom

Author: morphiex

Our CEO, Dr. Anthony Schwartz will be speaking at the 2020 CD47|SIRPa Summit to discuss the advantages of targeting SIRPa and thrombospondin-1 for the treatment of cancer. Morphiex's lead candidate (MBT-001) is the only drug that targets both SIRPa and thrombospondin-1.  #CD47 #SIRPalpha #cancer #immunotherapyhttps://www.cd47sirpa.com/ ...

New Data with MBT-001 An oral presentation (#O8) featuring our #CD47 inhibitor (MBT-001) titled "The Thrombospondin-1/CD47 signaling axis serve as potential markers of immune checkpoint blockade response modulating immune cell bioenergetics in the tumor microenvironment" will be presented on Saturday, November 9th, 2019 at the Gaylord...

Check out our new publication in the Journal of Immunology & Immunotherapy demonstrating the synergy of Morphiex's CD47 inhibitor (MBT-001) with ipilimumab (CTLA4) and CAR-T. https://link.springer.com/article/10.1007/s00262-019-02397-7 MBT-001 was developed at the National Cancer Institute (NCI) at the National Institutes of Health (NIH). MBT-001 is exclusively...

Our lead drug, MBT-001 was recently featured in Frontiers in Immunology for enhancing NK cells through the CD47-TSP-1 pathway. MBT-001 is the only CD47 treatment modality that inhibits both SIRPa "Don't eat me" and TSP-1, thereby eliciting the full cancer-killing potential of CD47. https://www.frontiersin.org/articles/10.3389/fimmu.2018.02985/full ...

Location

240 Newbury Street, 2nd Floor
Boston, MA
info@morphiex.com

Social Media

Twitter Facebook LinkedIn